Drug combinations for dyslipidemia and obesity treatment in metabolic syndrome.
Metabolic syndrome (MetS) is a cluster of risk factors, each one individually associated with increased cardiovascular disease risk. Treatment of all components of MetS is expected to result in reduced risk. Treatment of MetS mainly includes lifestyle changes. In addition, drug therapy may be considered, especially combinations of different drugs, in order to tackle all the features of MetS. We review the therapeutic strategies currently used for obesity and dyslipidemia treatment in patients with MetS, with a focus on drug combinations.
Florentin
M
M
Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece.
Elisaf
M S
MS
Mikhailidis
D P
DP
Liberopoulos
E N
EN
D000818:Animals; D019440:Anti-Obesity Agents / Q000627:therapeutic use*; D000924:Anticholesteremic Agents / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D050171:Dyslipidemias / Q000188:drug therapy* / Q000209:etiology*; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D024821:Metabolic Syndrome / Q000150:complications* / Q000188:drug therapy*; D009765:Obesity / Q000188:drug therapy* / Q000209:etiology*
D019440:Anti-Obesity Agents; D000924:Anticholesteremic Agents; D000960:Hypolipidemic Agents